Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Menu
Subscribe
Sign In
Register
Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Search Query
Submit Search
Show Search
Search Results
Submit
56,287 Results for "null"
Sort by
Relevance
Newest
Oldest
Premium
Haidar Is Down 50 Percent
The wildly volatile macro fund is one of the year’s worst-performing hedge funds.
Stephen Taub
December 11, 2023
Sponsored
Weak Demand and Hefty Supplies Continue to Weigh on Hog Markets
Sponsored by
CME Group
December 11, 2023
Sponsored
Trading Treasuries Around Major Economic Releases
Sponsored by
CME Group
December 11, 2023
Opinion
ESG Critics Ultimately May Help Improve the Strategies
Subjective and arbitrary decisions do affect ESG rankings — but ongoing challenges may lead to more accurate assessments.
Eric Uhlfelder
December 8, 2023
Corner Office
Larry Fink Says Republican Presidential Candidates Told Lies About BlackRock
The “political silly season” has started, says the manager’s chairman and CEO.
Michael Thrasher
December 7, 2023
Corner Office
Why an Asset Manager Paid Triple the Price of Rivals for the Same Research
“It’s been so difficult to understand what you should be paying,” says firm that compares research providers.
Alicia McElhaney
December 7, 2023
Premium
How Third Point Fared After Increasing Bets on Stocks
The multistrategy hedge fund headed by Dan Loeb doubled its net long exposure in November.
Stephen Taub
December 7, 2023
Portfolio
Big VC Funds Are Underperforming Smaller Ones and Their Future Is Dim
The smaller venture capital funds outperform large ones that have the presumed advantages of scale, brand, and experience, a report shows.
Michael Thrasher
December 6, 2023
Corner Office
‘Platform-Based’ Business Models Are Taking Over Asset Management
More firms are creating and deepening client relationships by doing far more than just investing.
Michael Thrasher
December 6, 2023
Premium
Prominent Hedge Funds Stand to Benefit From Biopharma’s Change of Plans
Weeks after Carmot Therapeutics filed for an IPO, the company chose a more lucrative way to monetize its potential.
Stephen Taub
December 6, 2023
1 of 5,629
Next
